Atorvastatin pharmacokinetic machinery

The Atorvastatin pharmacokinetic machinery refers to the integrated system of enzymes and transporters responsible for the absorption, distribution, metabolism, and excretion (ADME) of the HMG-CoA reductase inhibitor atorvastatin (Source: PharmGKB). Key components of this system include the hepatic uptake transporter Organic Anion Transporting Polypeptide 1B1 (OATP1B1, encoded by SLCO1B1), the primary phase I metabolizing enzyme Cytochrome P450 3A4 (CYP3A4), and efflux transporters such as P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) (Source: PubMed, PMID: 21534888). These proteins work in concert to determine the systemic bioavailability and the concentration of the drug at its therapeutic site in the liver (Source: StatPearls). Genetic polymorphisms in these components, most notably the SLCO1B1 c.521T>C variant, can significantly increase plasma concentrations of atorvastatin, thereby elevating the risk of adverse effects such as statin-associated muscle symptoms or life-threatening rhabdomyolysis (Source: CPIC Guidelines). Furthermore, this machinery is a major focal point for drug-drug interactions, as many common medications can inhibit or induce these specific enzymes and transporters, necessitating careful dose adjustment or alternative therapy (Source: FDA).

Other names

Atorvastatin ADME pathwayAtorvastatin disposition systemAtorvastatin metabolic pathwayAtorvastatin pharmacokinetic pathway

The machinery coordinates the hepatic entry, phase I oxidative metabolism, and biliary/renal efflux of atorvastatin to regulate its systemic bioavailability and intrahepatic concentration.